Optimum Nutrition
1
/
of
4
NMN
NMN
No reviews
No reviews
Regular price
$55.00 USD
Regular price
Sale price
$55.00 USD
Shipping calculated at checkout.
Quantity
Couldn't load pickup availability
The full picture
Everything Vyvata knows about this product — the score, the evidence, the FAQ, and where else to find shopper reviews. No hidden data. Every vendor is scored on the same published rubric — no brand can pay for placement. Read the rubric →
62/100
Standard
Six-dimension breakdown
Evidence
58
Formulation
62
Manufacturing
60
Safety
72
Transparency
58
Sustainability
50
Why this scored 62/100
Nicotinamide mononucleotide (NMN) is a direct NAD+ precursor with an emerging but genuine clinical evidence base — human trials (Yoshino 2021 in Science, Yamane 2023, Igarashi 2022, Kim 2022) have shown dose-dependent increases in whole-blood NAD+ at 250-1000 mg/day over 8-12 weeks, plus modest secondary outcomes on aerobic capacity and insulin sensitivity in specific populations. The evidence is younger and thinner than NR (nicotinamide riboside), and no NMN trial has yet demonstrated a hard longevity or all-cause-mortality endpoint. Bulkessentials sells NMN as a single-ingredient product — this is a positive for transparency but the title alone does not disclose dose (250 vs 500 vs 1000 mg), form (capsule vs powder vs sublingual), stability testing (NMN is notoriously moisture-sensitive), or third-party purity COAs. FDA in late 2022 issued a controversial position that NMN is excluded from being marketed as a dietary supplement because of its investigation as a drug candidate; this legal-gray-area status is a real caveat. Scored Standard — a real ingredient with real research, held back by disclosure gaps and regulatory uncertainty.
Last scored: Full rubric →
Evidence & sources
The Vyvata score's Evidence dimension measures the quality of published RCT support for a product's active ingredients at the label dose. Our source hierarchy: double-blind RCTs in MEDLINE-indexed journals > single-blind RCTs > open-label trials > observational studies > mechanism papers > N=1 case studies (anecdotes). Predatory journals and manufacturer-authored studies without independent replication are weighted down.
Product-specific evidence citations for this item are embedded in the analysis text on the "Analysis" tab. For the full framework and evidence hierarchy, see the methodology page.
How to read the Evidence dimension
- 80–100: Multiple double-blind RCTs in indexed journals directly testing this product OR the exact ingredients at the exact dose.
- 60–79: Single double-blind RCT + supporting ingredient literature at the studied dose.
- 40–59: Open-label trials + ingredient literature; no product-specific double-blind evidence.
- 20–39: Ingredient literature only; no product-specific trials or trials in predatory venues.
- 0–19: No credible evidence base or unverifiable claims.
FAQ data has not been generated for this product yet. See the site FAQ for general questions.
Customer reviews
Reviews on other platforms
The Vyvata score measures product integrity against a published rubric, not customer sentiment. Vyvata does not aggregate, republish, or license third-party reviews — the links below open search pages on their respective platforms.
All the data we have on this product
Every VSF-related metafield surfaced verbatim. Nothing hidden. If you spot data that looks wrong, let us know.
- VSF score
- 62 / 100
- Tier
- Standard
- Category
- Supplements
- Subcategory
- longevity cellular
- Last scored
- Third-party certifications
- None on record at time of scoring
- Vendor
- Bulkessentials
- Product type
- Specialty Supplements
- Tags
- Bulkessentials, Shopify Collective
Every score is set from the published rubric, audit-logged, and rescored whenever new evidence emerges (published trials, updated labels, third-party testing releases). Every vendor is scored on the same criteria — no pay-to-play. See our editorial-independence disclosure for the full policy, including brands with an editorial relationship to this site.
Share
